Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC

Summary

This open-label, multicenter, dose-escalation and expansion trial is designed to evaluate the safety and preliminary efficacy of inhaled DV281 in combination with nivolumabfor the treatment of NSCLC and to select a recommended phase 2 dose (RP2D).

Timeline

Start

2017-09-20

Primary completion

2019-09-19

Completion

2019-09-19

Drugs

Indications